Skip to main content
Premium Trial:

Request an Annual Quote

Compugen, Wrapping Up Evolution, Reports Zero Q4 Revenues

NEW YORK, Feb. 9 (GenomeWeb News) - Compugen said today that it had no revenues in the fourth quarter and reported an 8-percent decrease in net losses for the quarter.

 

"During 2005 we completed our evolution from a company providing life science software products and services on a fee basis, to a company that discovers and licenses potential therapeutic and diagnostic products to leading partners under milestone and revenue sharing agreements," stated Alex Kotzer, Compugen's president and CEO

 

The company said net loss for the period was $3.4 million (including a non-cash charge of $78,000 for amortization of deferred compensation), or $0.12 per share, compared with a net loss of $3.7 million (including a non-cash charge of $155,000 for amortization of deferred compensation), or $0.14 per share, for the corresponding quarter in 2004.

   

Compugen said R&D spending for the quarter slid to $2.3 million from $3.1 million a year ago.

 

The company had about $36.8 million in cash and cash equivalents as of Dec. 31.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.